科伦药业子公司在2025年欧洲肿瘤内科学会大会上公布多项创新药物研究成果

Core Viewpoint - The company announced that its subsidiary, Sichuan Kelun-Botai Biopharmaceutical Co., Ltd., presented multiple clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference held in Berlin from October 17 to 21 [1] Group 1 - The clinical research results include data on targeted antibody-drug conjugates (ADCs) such as sac-TMT (Jiatailai), targeting trophoblast cell surface antigen 2 (TROP2) [1] - The company also presented data on A166 (Shutailai), a HER2-targeted ADC [1] - Additionally, results related to Claudin18.2 (CLDN18.2) ADC SKB315 were shared [1]